Medical Technology

@xconomy.com 3 years ago

AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

@xconomy.com 5 years ago

Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial

@xconomy.com 5 years ago

CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells

@xconomy.com 5 years ago

Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M

@techcrunch.com 7 years ago

Oral arguments for who owns CRISPR-Cas9 starts next month

@techcrunch.com 7 years ago

CRISPR loses Nobel to tiny machines

@techcrunch.com 7 years ago

CRISPR will have to wait for that Nobel prize

@techcrunch.com 7 years ago

Reshaping human health and changing lives through gene editing

@techcrunch.com 8 years ago

Editas biotech stock drops by 26% over CRISPR patent dispute